Skip to content
The Joe Rogan ExperienceThe Joe Rogan Experience

Joe Rogan Experience #1234 - David Sinclair

David Sinclair, Ph.D., A.O. is a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School. He is best known for his work on understanding why we age and how to slow its effects. https://genetics.med.harvard.edu/sinclair/people/sinclair.php

Joe RoganhostDavid Sinclairguest
Jan 29, 20192h 21mWatch on YouTube ↗

CHAPTERS

  1. 0:01 – 1:10

    Anti-aging is now “on the table”: slowing, stopping, and reversing aging

    Joe opens by framing the big question: can we slow, stop, or even reverse aging? Sinclair says all of it is plausible based on lab results, and the challenge is translating it safely to humans.

    • Aging intervention is already routine in animal labs
    • Translation to humans is the next major hurdle
    • Sinclair’s confidence that multiple approaches are feasible
    • Sets the stage for lifestyle, supplements, and genetics
  2. 1:10 – 2:20

    Sinclair’s personal longevity routine: fasting, lifestyle stressors, and stacking interventions

    Joe pushes for the practical: what does Sinclair do himself? Sinclair outlines intermittent fasting, weight management, exercise, sauna/cold exposure, and the idea that these stressors activate survival pathways.

    • Intermittent fasting and meal-skipping as a practical routine
    • Timing of eating may matter as much as food composition
    • Heat/cold exposure as hormetic stress
    • Goal: trigger ‘defensive mode’ pathways tied to longevity
  3. 2:20 – 4:03

    Molecules that mimic (and amplify) diet and exercise: resveratrol and NMN

    Sinclair explains the strategy of mimicking fasting/exercise biology with compounds—and claims additive effects when combined with healthy behaviors. He recounts resveratrol results in obese mice and introduces NMN as a newer focus.

    • Compounds can be additive with fasting and exercise in animals
    • Resveratrol made obese mice metabolically healthier
    • Combining resveratrol with alternate-day feeding extended lifespan further
    • NMN described as producing “supercharged” performance in mice
  4. 4:03 – 6:19

    Sirtuins, NAD, NMN vs NR: the core biology behind Sinclair’s approach

    Sinclair steps back into the foundational discovery: sirtuin genes and their dependence on NAD. He explains how NAD declines with age and how NMN/NR aim to restore NAD to youthful levels.

    • Discovery of sirtuins as conserved aging regulators
    • Sirtuins require NAD to function; NAD drops roughly by half by ~50
    • NMN and NR raise NAD; NMN described as ‘fuel’ for sirtuins
    • Resveratrol as ‘accelerator pedal’ for sirtuin activity
  5. 6:19 – 13:26

    Supplement/drug details and pathways: dosages, metformin, AMPK/mTOR, and rapamycin cautions

    Joe asks for specifics: amounts, timing, side effects, and mechanisms. Sinclair describes his NMN and resveratrol regimen, then explains why he takes metformin off-label and how AMPK, sirtuins, and mTOR form three key longevity pathways.

    • Sinclair’s reported dosing: ~1g NMN AM + ~0.5g resveratrol; metformin at night
    • Metformin framed as protective against multiple diseases of aging
    • Three longevity pathways: AMPK (metformin), sirtuins (NMN/resveratrol), mTOR (protein sensing)
    • Rapamycin affects mTOR but is presented as too risky for casual use
  6. 13:26 – 24:05

    Protein, mTOR, red meat concerns, and the performance vs longevity trade-off

    They move from pills to diet composition—especially protein. Sinclair argues high amino acids activate mTOR and may shorten lifespan, discussing red meat/TMAO, branched-chain amino acids, and evolutionary trade-offs like ‘disposable soma.’

    • Red meat concerns: TMAO and heart disease signals (mouse evidence noted)
    • High amino acids/BCAAs activate mTOR; may trade short-term gains for long-term costs
    • Disposable soma theory: growth/reproduction vs long-term maintenance
    • Sinclair’s preference for fish/white meat and lots of vegetables/polyphenols
  7. 24:05 – 29:10

    Aging as a disease and the societal stakes: overpopulation, economics, and ‘healthspan’

    Sinclair argues aging should be classified as a disease and frames it as the dominant driver of healthcare and economic burden. Joe raises overpopulation fears; Sinclair counters with demographic/education arguments and projected stabilization.

    • Rationale: aging isn’t classified as disease mainly because it’s universal
    • Healthspan focus: prevent frailty/dementia rather than extend sick years
    • Overpopulation debate and demographic tapering models (~9–10B)
    • Women’s education and prosperity linked to lower fertility rates
  8. 29:10 – 32:18

    Blue Zones and the enduring basics: Okinawa, caloric restriction, and intermittent fasting

    Joe asks where people live longest; Sinclair highlights Blue Zones, especially Okinawa, and emphasizes not overeating. They connect decades of calorie restriction data to intermittent fasting as a sustainable alternative.

    • Okinawa: frequent centenarians, physical activity, vegetables, fasting
    • ‘Stop at 70%’/avoid chronic overeating as a key theme
    • Calorie restriction extends lifespan robustly in many organisms
    • Intermittent fasting as a practical mimic of calorie restriction
  9. 32:18 – 38:30

    Stress, radiation, and the epigenome: the ‘scratched DVD’ theory of aging

    Sinclair explains why he avoids unnecessary X-rays/scanners and pivots to epigenetics. He lays out a model where aging is driven less by DNA mutations and more by epigenetic information loss—like a reader that can’t properly access the genome.

    • Stress management as part of longevity strategy
    • DNA breaks and repair disrupt epigenetic ‘gene-reading’ over time
    • CD/DVD analogy: genome is digital; epigenome/reader is vulnerable and degrades
    • Goal: restore epigenetic information and reduce ‘informational noise’
  10. 38:30 – 46:05

    Cellular reprogramming and vision restoration: mouse results and planned human trials

    Joe presses on the sci-fi edge: can you reset age? Sinclair describes partial reprogramming using a small set of genes delivered by viral vectors, with striking mouse eye/optic nerve results and a proposed glaucoma-focused clinical path.

    • Reprogramming genes can make cells ‘younger again’ in models
    • Mouse studies: optic nerve crush repair, glaucoma model recovery, old-mouse vision improvement
    • Delivery via viral vectors injected into the eye; genes controlled by an antibiotic switch
    • Human safety trials discussed with a timeline around early 2020 (as stated)
  11. 46:05 – 52:54

    Monitoring and optimization: InsideTracker, blood tests, exercise structure, and avoiding extremes

    Sinclair explains how he determines “the right balance” through frequent testing and tracking rather than annual checkups. They discuss fasted workouts, trainers, high-intensity/low-impact exercise, and the hormesis ‘sweet spot.’

    • Regular blood testing every few months and trend tracking (InsideTracker)
    • Metformin use partly driven by rising glucose markers
    • Exercise: low-impact high-intensity, weights for muscle/bone, avoid overtraining
    • Hormesis framing: enough stress to trigger repair, not so much to cause damage
  12. 52:54 – 1:29:16

    Everyday diet details and supplement skepticism: caffeine, Diet Coke, probiotics, vitamins, and iron

    They zoom into practical habits: coffee/caffeine limits, Diet Coke as a vice, yogurt/ferments for the microbiome, and minimal vitamin supplementation. Sinclair stresses measuring deficiencies rather than taking ‘expensive urine’ multivitamins, and flags concern about excess iron and senescent ‘zombie’ cells.

    • Microbiome concerns with artificial sweeteners; yogurt/fermented foods as support
    • Vitamin D + K2 as his main vitamins; otherwise diet-first approach
    • Iron overload concerns in older age; uncertainty about thresholds
    • Household bans on sugary sodas/smoothies; sugar reduction focus
  13. 1:29:16 – 1:35:33

    Government and biodefense work: anthrax decontamination, biofilms, and rapid pathogen detection

    Sinclair describes advisory work related to biodefense and outbreak detection. He shares examples: developing enzyme-based solutions to neutralize anthrax/biofilms and building tools to identify unknown pathogens from samples much faster than traditional culture methods.

    • Biosecurity risks: engineered organisms and pandemic-scale threats
    • Enzyme ‘cocktail’ concept for decontamination (anthrax) and biofilm removal
    • Metagenomic detection: identify all organisms in a blood drop/swab
    • Critique of slow legacy microbiology workflows (culture-based methods)
  14. 1:35:33 – 1:55:48

    Lyme disease as a systems failure: diagnosis delays, CRISPR tick solutions, and microbial diversity

    A personal story: Sinclair’s daughter’s severe Lyme illness and his frustration with slow/insufficient diagnostic pathways. They discuss tick-borne diseases, potential CRISPR-based ecological interventions, and how vast unknown microbial diversity complicates prevention and treatment.

    • Lyme can present without bullseye rash; delayed treatment can be severe
    • Need for faster diagnostics to enable timely antibiotics
    • CRISPR-based approaches proposed to reduce Lyme vectors/pathogens
    • Global microbiome diversity: many organisms unknown; regional variation matters
  15. 1:55:48 – 2:21:04

    The messy reality of frontier science: backlash, conflicts of interest, and building ethical longevity companies

    They close by discussing the competitiveness of science, Sinclair’s career controversies (resveratrol mechanism disputes), and the brutal cost of clinical trials. Sinclair explains transparency/conflict-of-interest safeguards and his intent to build pharma-style companies that prioritize broad benefit over price gouging.

    • Scientific politics: public attacks, replication battles, and career risk
    • Resveratrol mechanism controversy and eventual experimental vindication
    • Clinical trial pipeline (phases 1–3) and massive costs to reach market
    • Disclosure, cease-and-desist actions, and ethics-driven pricing philosophy

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.